160 related articles for article (PubMed ID: 29848970)
21. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
[TBL] [Abstract][Full Text] [Related]
22. Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease.
Karlas T; Weise L; Kuhn S; Krenzien F; Mehdorn M; Petroff D; Linder N; Schaudinn A; Busse H; Keim V; Pratschke J; Wiegand J; Splith K; Schmelzle M
J Transl Med; 2017 May; 15(1):106. PubMed ID: 28521774
[TBL] [Abstract][Full Text] [Related]
23. Na/K-ATPase as a target for anticancer drugs: studies with perillyl alcohol.
Garcia DG; de Castro-Faria-Neto HC; da Silva CI; de Souza e Souza KF; Gonçalves-de-Albuquerque CF; Silva AR; de Amorim LM; Freire AS; Santelli RE; Diniz LP; Gomes FC; Faria MV; Burth P
Mol Cancer; 2015 May; 14():105. PubMed ID: 25976744
[TBL] [Abstract][Full Text] [Related]
24. Circulating progenitor cells: a comparison of patients with glioblastoma or meningioma.
Alexiou GA; Vartholomatos G; Karamoutsios A; Batistatou A; Kyritsis AP; Voulgaris S
Acta Neurol Belg; 2013 Mar; 113(1):7-11. PubMed ID: 22688590
[TBL] [Abstract][Full Text] [Related]
25. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
[TBL] [Abstract][Full Text] [Related]
26. Metformin influences progression in diabetic glioblastoma patients.
Adeberg S; Bernhardt D; Ben Harrabi S; Bostel T; Mohr A; Koelsche C; Diehl C; Rieken S; Debus J
Strahlenther Onkol; 2015 Dec; 191(12):928-35. PubMed ID: 26329695
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.
Tichy J; Spechtmeyer S; Mittelbronn M; Hattingen E; Rieger J; Senft C; Foerch C
J Neurooncol; 2016 Jan; 126(2):361-9. PubMed ID: 26518540
[TBL] [Abstract][Full Text] [Related]
28. Significance of liquid biopsy in glioblastoma - A review.
Klekner Á; Szivos L; Virga J; Árkosy P; Bognár L; Birkó Z; Nagy B
J Biotechnol; 2019 Jun; 298():82-87. PubMed ID: 30986516
[TBL] [Abstract][Full Text] [Related]
29. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
30. Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases.
Chen TC; Da Fonseca CO; Schönthal AH
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598140
[TBL] [Abstract][Full Text] [Related]
31. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
Greenfield JP; Jin DK; Young LM; Christos PJ; Abrey L; Rafii S; Gutin PH
Neurosurgery; 2009 May; 64(5):819-26; discussion 826-7. PubMed ID: 19404145
[TBL] [Abstract][Full Text] [Related]
32. Emerging circulating biomarkers in glioblastoma: promises and challenges.
Touat M; Duran-Peña A; Alentorn A; Lacroix L; Massard C; Idbaih A
Expert Rev Mol Diagn; 2015; 15(10):1311-23. PubMed ID: 26394701
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant effect of low-carbohydrate diet on outcomes of patients with recurrent glioblastoma under intranasal perillyl alcohol therapy.
Santos JG; Faria G; Cruz WDCSD; Fontes CA; Schönthal AH; Quirico-Santos T; da Fonseca CO
Surg Neurol Int; 2020; 11():389. PubMed ID: 33282452
[TBL] [Abstract][Full Text] [Related]
34. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
35. Serum amyloid A1 is upregulated in human glioblastoma.
Knebel FH; Uno M; Galatro TF; Bellé LP; Oba-Shinjo SM; Marie SKN; Campa A
J Neurooncol; 2017 May; 132(3):383-391. PubMed ID: 28283801
[TBL] [Abstract][Full Text] [Related]
36. Cell Free DNA and Procalcitonin as Early Markers of Complications in ICU Patients with Multiple Trauma and Major Surgery.
Ahmed AI; Soliman RA; Samir S
Clin Lab; 2016 Dec; 62(12):2395-2404. PubMed ID: 28164563
[TBL] [Abstract][Full Text] [Related]
37. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
38. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study.
Czarnek N; Clark K; Peters KB; Mazurowski MA
J Neurooncol; 2017 Mar; 132(1):55-62. PubMed ID: 28074320
[TBL] [Abstract][Full Text] [Related]
39. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.
Cachia D; Elshafeey NA; Kamiya-Matsuoka C; Hatami M; Alfaro-Munoz KD; Mandel JJ; Colen R; DeGroot JF
J Neurooncol; 2017 Oct; 135(1):75-81. PubMed ID: 28702781
[TBL] [Abstract][Full Text] [Related]
40. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
